Influenza viruses are RNA viruses from the Orthomyxoviridae family. They cause the influenza epidemic (the flu) with symptoms similar to those of COVID-19, including fevers, sore throats, and coughs. There are four types of influenza viruses, known as influenza viruses A, B, C, and D. Influenza A virus and influenza B virus are the most common pathogenic virus types in humans, causing millions of infections worldwide each year. Notably, seasonal influenza A virus frequently mutates to evade immunity through “antigenic drift”, which occurs in the genes of virus surface glycoproteins, hemagglutinin (H), and neuraminidase (N). These mutations result in over a hundred variant combinations, among which subtypes H1N1 and H3N2 are routinely reported to circulate globally.
The influenza A virus genome contains eight RNA segments encoding proteins that are essential for host infection, viral replication, virion assembly, and transmission (Figure 1). These proteins include three RNA polymerases, PB1, PB2, and PA, that are fused with nucleoprotein (NP) to form nucleus complexes required for viral genome replication. The viral nucleus complex is encircled by a host-derived lipid bilayer envelope that is embedded with matrix protein (M1), ion channel protein (M2), neuraminidase (NA), surface glycoproteins (H and N), and nuclear export protein (NEP), which is the assembly process required for the viral particle to begin the transmission stage. The non-structural protein NS1 then circumvents the host immune response for viral production to occur.
Figure 1. Influenza Virus Structure. The virus consists of RNA polymerases (PB1, PB2, and PA), nucleoprotein (NP), matrix protein (M1), ion channel protein (M2), neuraminidase (NA), surface glycoproteins (H and N), and nuclear export protein (NEP), and non-structural protein (NS1).
Leadgene has established a reputation for providing raw materials for rapid COVID-19 test devices. We have now expanded the existing catalog with the release of a series of influenza virus antibodies and proteins for developing assay tools to detect both the influenza A virus and the influenza B virus. These reagents mark another one of Leadgene’s milestones to support diagnostics of infectious diseases.
Recognize Influenza A virus NP in Lateral Flow and ELISA, when recombinant LGA3 antibody
was paired with Anti-Influenza A virus NP Antibody [clone IA05] (cat. 15871).
Recognize Influenza A virus NP in ELISA, when clone IA06 antibody was paired with AntiInfluenza A virus NP Antibody [clone IA05] (cat. 15871).
Recognize Influenza B virus NP in Lateral Flow, when clone IB05 antibody was paired with AntiInfluenza B virus NP Antibody [clone IB06] (cat. 16271).
Recognize Influenza B virus NP in Lateral Flow, when clone IB06 antibody was paired with AntiInfluenza B virus NP Antibody [clone IB05] (cat. 16171).